A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.

Conditions

• NSCLC (Advanced Non-small Cell Lung Cancer)
• NSCLC (Non-small Cell Lung Cancer)
• NSCLC (Non-small Cell Lung Carcinoma)
• NSCLC
• Melanoma (Skin Cancer)
• Melanoma (Skin) Stage IV
• CRC
• MSI High Colorectal Cancer
• DMMR Colorectal Cancer
• RCC, Renal Cell Cancer
• RCC
• Solid Tumors
• Metastatic Solid Tumors
• Advanced Solid Tumors
• Advanced Solid Tumors Cancer

Interventions

• DEVICE: Signatera Genome ultra-sensitive ctDNA blood test

Sponsor

Natera, Inc.